Anne-Marie Koop

4 175 13. Liu A, Philip J, Vinnakota KC, Bergh F Van den, Tabima DM, Hacker T, Beard DA, Chesler NC. Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension. Physiol Rep 2017;5:1–12. 14. Redout EM, Wagner MJ, Zuidwijk MJ, Boer C, Musters RJP, Hardeveld C van, Paulus WJ, Simonides WS. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res W.S. Simonides, Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, Netherlands; 2007;75:770–781. 15. Faber MJ, Dalinghaus M, Lankhuizen IM, Bezstarosti K, Dekkers DHW, Duncker DJ, Helbing WA, Lamers JMJ. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: Correlations with the degree of hypertrophy. Proteomics J.M.J. Lamers, Department of Biochemistry, Cardiovascular Research School COEUR, Erasmus MC, 3000 DR Rotterdam, Netherlands; 2005;5:2519–2530. 16. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med E.D. Michelakis, Department of Medicine, University of Alberta, Edmonton, AB T6G 2B7, Canada; 2013;91:1315–1327. 17. Nagendran J, Gurtu V, Fu DZ, Dyck JRB, Haromy A, Ross DB, Rebeyka IM, Michelakis ED. A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg E.D. Michelakis, Pulmonary Hypertension Program, Department of Medicine, University of Alberta, Edmonton, Alta., Canada; 2008;136:168-178.e3. 18. Gomez-Arroyo J, Mizuno S, Szczepanek K, Tassell B Van, Natarajan R, Remedios CG Dos, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Hear Fail 2013;6:136–144. 19. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J. Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care M ed 2014;189:325–334. 20. Bruggen CE van der, Happé CM, Dorfmüller P, Trip P, Spruijt OA, Rol N, Hoevenaars FP, Houweling AC, Girerd B, Marcus JT, Mercier O, Humbert M, Handoko ML, Velden J van der, Vonk Noordegraaf A, Bogaard HJ, Goumans M-J, Man FS de. Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial HypertensionCLINICAL PERSPECTIVE. Circulation 2016;133:1747–1760. 21. Veerdonk MC van de, Bogaard HJ, Voelkel NF. The right ventricle and pulmonary hypertension. Heart Fail Rev 2016; 22. Albada ME van, Berger RMF, Niggebrugge M, Veghel R van, Cromme-Dijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension. Eur J Pharmacol M.E. van Albada, Department of Pediatrics, Division of Pediatric Cardiology, Beatrix Children’s Hospital, Groningen, Netherlands; 2006;549:107–116.